Media Thread, page-13927

Not sure if this has already been discussed on this forum, but the following link is an Analyst Coverage from Diamond Equity Research dated 22nd May 2024. They are probably paid by Imugene to commission this report.

From the report they have a target valuation price of 49c a share, assuming updates of trials are positive.

https://static1.squarespace.com/static/5b63d41b3e2d09b1f56bf483/t/664ec9137f9a8f6d4e17dcd8/1716439317778/Imugene+May+2024+Update+Note.pdf

Points from the report:

Azer-cel Allogeneic CAR T Cell Therapy: Preliminary data from these trials are expected in H2 2024

Vaxinia Mast Trial: Expected to provide preliminary data in H2 2024.

OnCARlytics (CF33-CD19): Preliminary data from the combination trials are anticipated by Q4 2024

B Cell Immunotherapy PD1-Vaxx: Targeting to release early data in 2025.

B Cell Immunotherapy HER-Vaxx: Current business development discussions continue to explore its application in various cancers, including gastric, breast, ovarian, lung, and pancreatic cancers.

So basically expecting clinical data updates in the second half of the year on most of their therapies. Would suggest that Q3 will probably be lacking in news with share price drifting lower before updates start to flow in Q4 of this year. Hopefully good news to get share price moving upwards again.

HER-Vaxx appears to be on-hold pending any successful discussions with third parties.

GLTA.